An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer, even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed. This discovery could eventually lead to a new class of drugs to treat NSCLC and potentially other cancers.
When activated in ovarian cancer cells, the receptor for the body’s primary stress hormone alters the tumor environment in ways that blunt immune response, according to research led by UT Southwestern Medical Center.
